Benitec Biopharma Inc. announces it has entered into a securities purchase agreement to issue 5,749,152 shares of the Company?s common stock at a issue price of $4.80 per share for gross proceeds of $27,595,929.6 and pre-funded warrants to purchase up to an aggregate of 2,584,239 shares of Common Stock at a issue price of $4.7999 per Pre-Funded Warrant for gross proceeds of $ 12,404,088.7761 for gross proceeds of $40,000,018.3761 on April 17, 2024. Each Pre-Funded Warrant has an exercise price of $0.0001 per Pre-Funded Warrant Share. The Pre-Funded Warrants are exercisable at any time after their original issuance and will expire when exercised in full.

The transaction will include participation from Suvretta Capital Management, LLC, as lead investor, Adage Capital Partners L.P., Nantahala Capital, multiple healthcare-focused funds, Pinehurst Partners, L.P, Corbin Sustainability & Engagement Fund, L.P,Nantahala Capital Partners Limited Partnership, NCP RFM LP, Blackwell Partners LLC - Series A, Schonfeld Global Master Fund L.P, NEAMAN ASSET MANAGEMENT, LLC, HBM Healthcare Investments (Cayman) Ltd, Special Situations Fund III QP, L.P, Special Situations Cayman Fund, L.P, Special Situations Life Sciences Fund, PhiFund, LP, Alyeska Master Fund, LP, Averill Madison Master Fund, Ltd, Averill Master Fund, Ltd and Franklin Biotechnology Discovery Fund.The transaction is expected to close on April 22, 2024.